Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Intrinsic Value
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. [ Read More ]
The intrinsic value of one TEVA stock under the Base Case scenario is 15.15 USD. Compared to the current market price of 14.43 USD, Teva Pharmaceutical Industries Ltd is Undervalued by 5%.
Valuation Backtest
Teva Pharmaceutical Industries Ltd
Run backtest to discover the historical profit from buying and selling TEVA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Company Boosts Revenue Outlook for 2023
2023-Q2 Earnings Call
The company's revenue grew by 4% to $3.9 billion, with a strengthened adjusted EBITDA at $1.1 billion, leading to an increase in the revenue outlook for 2023 to a range of $15 billion to $15.4 billion. Notable growth was seen in its innovative treatments AUSTEDO and AJOVY, with AUSTEDO revenues jumping 51% for the quarter and AJOVY growing by 17%, contributing to overall international growth. The company confirmed its full-year free cash flow guidance of $1.7 billion to $2.1 billion and aims to significantly reduce net debt, which stands at $18 billion, working towards a targeted net debt to EBITDA ratio of two times by the end of 2027.
Balance Sheet Decomposition
Teva Pharmaceutical Industries Ltd
Current Assets | 12.5B |
Cash & Short-Term Investments | 3.2B |
Receivables | 3.4B |
Other Current Assets | 5.9B |
Non-Current Assets | 31B |
PP&E | 6.1B |
Intangibles | 22.6B |
Other Non-Current Assets | 2.3B |
Current Liabilities | 12.2B |
Accounts Payable | 2.6B |
Accrued Liabilities | 3.4B |
Short-Term Debt | 23m |
Other Current Liabilities | 6.2B |
Non-Current Liabilities | 23.7B |
Long-Term Debt | 18.2B |
Other Non-Current Liabilities | 5.6B |
Earnings Waterfall
Teva Pharmaceutical Industries Ltd
Revenue
|
15.8B
USD
|
Cost of Revenue
|
-7.9B
USD
|
Gross Profit
|
8B
USD
|
Operating Expenses
|
-4.4B
USD
|
Operating Income
|
3.5B
USD
|
Other Expenses
|
-4.1B
USD
|
Net Income
|
-559m
USD
|
Free Cash Flow Analysis
Teva Pharmaceutical Industries Ltd
What is Free Cash Flow?
TEVA Profitability Score
Profitability Due Diligence
Teva Pharmaceutical Industries Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Teva Pharmaceutical Industries Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
TEVA Solvency Score
Solvency Due Diligence
Teva Pharmaceutical Industries Ltd's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Teva Pharmaceutical Industries Ltd's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TEVA Price Targets Summary
Teva Pharmaceutical Industries Ltd
According to Wall Street analysts, the average 1-year price target for TEVA is 15.13 USD .
Shareholder Return
TEVA Price
Teva Pharmaceutical Industries Ltd
Average Annual Return | -10% |
Standard Deviation of Annual Returns | 28.2% |
Max Drawdown | -62% |
Market Capitalization | 59.5B ILS |
Shares Outstanding | 11 256 860 |
Percentage of Shares Shorted |
N/A
|
TEVA News
Last Important Events
Teva Pharmaceutical Industries Ltd
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Teva Pharmaceutical Industries Ltd
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Contact
IPO
Employees
Officers
The intrinsic value of one TEVA stock under the Base Case scenario is 15.15 USD.
Compared to the current market price of 14.43 USD, Teva Pharmaceutical Industries Ltd is Undervalued by 5%.